JSPR Jasper Therapeutics, Inc.

Nasdaq www.jaspertherapeutics.com


$ 2.49 $ -0.12 (-4.62 %)    

Thursday, 16-Oct-2025 16:28:47 EDT
QQQ $ 598.23 $ -2.23 (-0.37 %)
DIA $ 458.84 $ -3.15 (-0.68 %)
SPY $ 658.90 $ -4.53 (-0.68 %)
TLT $ 91.49 $ 0.68 (0.75 %)
GLD $ 401.79 $ 9.06 (2.34 %)
$ 2.48
$ 2.64
$ 2.35 x 100
$ 2.66 x 100
$ 2.47 - $ 2.65
$ 2.22 - $ 26.05
245,089
na
38.03M
$ 2.18
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-12-2025 03-31-2025 10-Q
3 02-28-2025 01-01-1970 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 03-05-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-11-2023 06-30-2023 10-Q
10 05-12-2023 03-31-2023 10-Q
11 03-08-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-12-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-18-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-16-2021 06-30-2021 10-Q
18 05-24-2021 03-31-2021 10-Q
19 03-30-2021 12-31-2020 10-K
20 11-10-2020 09-30-2020 10-Q
21 08-14-2020 06-30-2020 10-Q
22 05-13-2020 03-31-2020 10-Q
23 03-26-2020 12-31-2019 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 evercore-isi-group-maintains-outperform-on-jasper-therapeutics-lowers-price-target-to-14

Evercore ISI Group analyst Gavin Clark-Gartner maintains Jasper Therapeutics (NASDAQ:JSPR) with a Outperform and lowers the ...

 jmp-securities-maintains-market-outperform-on-jasper-therapeutics-lowers-price-target-to-6

JMP Securities analyst Silvan Tuerkcan maintains Jasper Therapeutics (NASDAQ:JSPR) with a Market Outperform and lowers the p...

 btig-maintains-buy-on-jasper-therapeutics-lowers-price-target-to-7

BTIG analyst Justin Zelin maintains Jasper Therapeutics (NASDAQ:JSPR) with a Buy and lowers the price target from $20 to $7.

 jasper-therapeutics-announces-proposed-underwritten-public-offering-of-its-common-stock-no-financial-terms-disclosed

Jasper Therapeutics, Inc. (NASDAQ:JSPR) ("Jasper"), a clinical-stage biotechnology company focused on development of br...

 ubs-maintains-buy-on-jasper-therapeutics-lowers-price-target-to-25

UBS analyst Trung Huynh maintains Jasper Therapeutics (NASDAQ:JSPR) with a Buy and lowers the price target from $29 to $25.

 jasper-therapeutics-q2-eps-174-misses-140-estimate

Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(1.74) per share which missed the analyst consensus estimate of...

 jasper-therapeutics-announces-50-workforce-reduction-and-strategic-refocus-on-chronic-urticaria-programs-to-extend-cash-runway-and-advance-briquilimab-development

Reducing workforce by approximately 50% to focus on Chronic Urticaria programs and extend cash runwayDr. Edwin Tucker departing...

 bmo-capital-downgrades-jasper-therapeutics-to-market-perform-lowers-price-target-to-4

BMO Capital analyst Kostas Biliouris downgrades Jasper Therapeutics (NASDAQ:JSPR) from Outperform to Market Perform and lowe...

 jmp-securities-maintains-market-outperform-on-jasper-therapeutics-lowers-price-target-to-12

JMP Securities analyst Silvan Tuerkcan maintains Jasper Therapeutics (NASDAQ:JSPR) with a Market Outperform and lowers the p...

 evercore-isi-group-maintains-outperform-on-jasper-therapeutics-lowers-price-target-to-20

Evercore ISI Group analyst Gavin Clark-Gartner maintains Jasper Therapeutics (NASDAQ:JSPR) with a Outperform and lowers the ...

 william-blair-downgrades-jasper-therapeutics-to-market-perform

William Blair analyst Matt Phipps downgrades Jasper Therapeutics (NASDAQ:JSPR) from Outperform to Market Perform.

 hc-wainwright--co-maintains-buy-on-jasper-therapeutics-lowers-price-target-to-20

HC Wainwright & Co. analyst Emily Bodnar maintains Jasper Therapeutics (NASDAQ:JSPR) with a Buy and lowers the price tar...

 btig-maintains-buy-on-jasper-therapeutics-lowers-price-target-to-20

BTIG analyst Justin Zelin maintains Jasper Therapeutics (NASDAQ:JSPR) with a Buy and lowers the price target from $64 to $20.

 jasper-therapeutics-shares-fall-on-briquilimab-drug-lot-problem

Jasper shares drop after updated BEACON study shows strong results but faces disruption from compromised drug product lot and h...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION